PCM
GBT

Prelude Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Prelude Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$5K – 2357
2019
Q3 		$5K Buy
+100
New +$5.21K ﹤0.01% 1569
2018
Q4 		– Sell
-4,000
Closed -$152K – 2279
2018
Q3 		$152K Buy
4,000
+3,500
+700% +$155K 0.01% 851
2018
Q2 		$23K Buy
+500
New +$22.8K ﹤0.01% 1329
2018
Q1 		– Sell
-2,500
Closed -$98K – 1789
2017
Q4 		$98K Buy
+2,500
New +$93.4K 0.01% 792
2017
Q3 		– Sell
-2,200
Closed -$60K – 1977
2017
Q2 		$60K Hold
2,200
– – 0.01% 952
2017
Q1 		$81K Buy
+2,200
New +$55.4K 0.01% 856
2016
Q4 		– Sell
-600
Closed -$14K – 1856
2016
Q3 		$14K Buy
+600
New +$11.4K ﹤0.01% 1391

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's GBT Position: Q4 2022 in Review

Prelude Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 125,029 shares — an estimated $8.51M sold.

Prelude Capital Management first reported a position in GBT in Q3 2016 and held it in 16 quarters. The position peaked at $8.51M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Prelude Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 125,029 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.51M.
  • Prelude Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 16 quarters.
  • Prelude Capital Management's Global Blood Therapeutics, Inc. position peaked at $8.51M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.